Acetazolamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Acetazolamide
- Acetazolamide: From Glaucoma and Heart Failure to Exercise-Induced Malignant Hyperthermia
Acetazolamide: From Glaucoma and Heart Failure to Exercise-Induced Malignant Hyperthermia
One-Sentence Summary
Acetazolamide is a carbonic anhydrase inhibitor, originally used for glaucoma, absence epilepsy, congestive heart failure and altitude sickness. The TxGNN model predicts it may be effective for exercise-induced malignant hyperthermia, but no clinical trials and no publications currently support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Open-angle glaucoma, angle-closure glaucoma, absence epilepsy, congestive heart failure, altitude sickness (the Singapore licence records contain no indication text, so these come from the knowledge graph) |
| Predicted New Indication | Exercise-induced malignant hyperthermia |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available. Based on known information, acetazolamide is a carbonic anhydrase inhibitor. Its efficacy in glaucoma, epilepsy, heart failure and altitude sickness is established, and it may mechanistically influence muscle pH and ion handling.
The link to exercise-induced malignant hyperthermia is speculative. It is a graph-based inference with no supporting trial or literature data. The very high score (99.95%) reflects network proximity, not demonstrated clinical benefit.
Other predictions in the same list (ranked 2 to 10) have somewhat more indirect evidence, but none reaches Phase 2/3 trial-level support. Examples are hypertrophic cardiomyopathy and cardiomyopathy, supported only by heart failure reviews, case reports and one animal study. For intestinal obstruction, the literature points to harm (acetazolamide-induced ileus).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16860P | GP-Acetazolamide Tablet 250 mg (GPAX Pharmaceuticals) | Tablet | Not stated in the data compiled |
| SIN01140P | AA Pharma Acetazolamide Tablet 250 mg (Apotex) | Tablet | Not stated in the data compiled |
Safety Considerations
- Contraindications (from knowledge-graph associations, not label text): liver failure, liver disease, kidney disease, renal tubular acidosis, hematologic disease, gallbladder disease, gout, respiratory failure, type 1 and type 2 diabetes mellitus, diabetic ketoacidosis, and adrenal insufficiency conditions (Addison disease, congenital adrenal hyperplasia, adrenocortical insufficiency and related disorders).
- Drug Interactions: 100 interactions were identified. Those shown include:
- Major: acetylsalicylic acid (aspirin), cisapride.
- Moderate: antidiabetic agents (acarbose, acetohexamide, alogliptin, canagliflozin, chlorpropamide, dapagliflozin, albiglutide, dulaglutide), corticosteroids (beclomethasone, betamethasone, dexamethasone), amphotericin B formulations, and laxatives (bisacodyl, castor oil).
- Minor: doxycycline.
- Case-report safety signals: non-cardiogenic pulmonary edema after intravenous acetazolamide, and acetazolamide-induced adynamic ileus. Acetazolamide may also worsen metabolic acidosis and raise ammonia in cirrhosis.
Package insert warnings were not available. Please refer to the package insert for the full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for exercise-induced malignant hyperthermia has no trials or publications (L5), and the mechanistic link is unconfirmed. The drug is already marketed in Singapore, but only for its existing indications, and the safety profile includes notable contraindications and interactions.
To proceed, the following is needed:
- Mechanism of action data and a supported mechanistic rationale for the new indication
- Package insert warnings and contraindications from HSA, which are required for safety screening
- Preclinical or clinical evidence in the predicted condition
- Review of whether the higher-ranked alternatives (e.g., cardiomyopathy-related conditions) deserve evaluation, bearing in mind the safety signals identified (pulmonary edema, ileus, acidosis)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.